{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:35Z","timestamp":1791388115875,"version":"4.3.3"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ncl.2025.05.015","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:49:06Z","timestamp":1756813746000},"page":"761-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chronic Inflammatory Demyelinating Polyneuropathy and Variants"],"prefix":"10.1016","volume":"43","author":[{"given":"Amro M.","family":"Stino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen M.","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ncl.2025.05.015_bib1","first-page":"621","article-title":"Chronic inflammatory polyradiculoneuropathy","volume":"50","author":"Dyck","year":"1975","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.ncl.2025.05.015_bib2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/archneur.1989.00520440064022","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria","volume":"46","author":"Barohn","year":"1989","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2025.05.015_bib3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.015_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"Laughlin","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2025.05.015_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.0000000000001833","article-title":"CIDP diagnostic pitfalls and perception of treatment benefit","volume":"85","author":"Allen","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.015_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jns.12344","article-title":"Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"24","author":"Bunschoten","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.015_bib7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/jns.12479","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision","volume":"27","year":"2022","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.015_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/WCO.0000000000000725","article-title":"Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"32","author":"Pascual-Goni","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"21","key":"10.1016\/j.ncl.2025.05.015_bib9","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study","volume":"74","author":"Ruts","year":"2010","journal-title":"Neurology"},{"issue":"8 Suppl 3","key":"10.1016\/j.ncl.2025.05.015_bib10","first-page":"S8","article-title":"Research criteria for defining patients with CIDP","volume":"60","author":"Sander","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.015_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1085-9489.2005.10302.x","volume":"10","author":"Joint Task Force of the","year":"2005","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.015_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1529-8027.2010.00245.x","volume":"15","author":"Joint Task Force of the","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.015_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2025.05.015_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/mus.27954","article-title":"Anti-myelin-associated glycoprotein neuropathy: where do we stand?","volume":"68","author":"Stino","year":"2023","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.015_bib15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/(SICI)1097-4598(199905)22:5<560::AID-MUS2>3.0.CO;2-Q","article-title":"Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome","volume":"22","author":"Saperstein","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2025.05.015_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577170","article-title":"Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes","volume":"341","author":"Shibuya","year":"2020","journal-title":"J Neuroimmunol"},{"issue":"14","key":"10.1016\/j.ncl.2025.05.015_bib17","doi-asserted-by":"crossref","first-page":"e1392","DOI":"10.1212\/WNL.0000000000012618","article-title":"Pure Motor Onset and IgM-gammopathy occurrence in multifocal acquired demyelinating sensory and motor neuropathy","volume":"97","author":"Beecher","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2025.05.015_bib18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1136\/jnnp.2009.179358","article-title":"Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study","volume":"80","author":"Rajabally","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"10.1016\/j.ncl.2025.05.015_bib19","doi-asserted-by":"crossref","first-page":"e1470","DOI":"10.1212\/WNL.0000000000008978","article-title":"Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies","volume":"94","author":"Herraets","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2025.05.015_bib20","doi-asserted-by":"crossref","first-page":"e1745","DOI":"10.1212\/WNL.0000000000010369","article-title":"Nerve ultrasound for diagnosing chronic inflammatory neuropathy: a multicenter validation study","volume":"95","author":"Herraets","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.015_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mus.27709","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy","volume":"66","author":"Allen","year":"2022","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.015_bib22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2025.05.015_bib23","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2025.05.015_bib24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40264-023-01326-z","article-title":"Safety and tolerability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: results of the ProCID Study","volume":"46","author":"Cornblath","year":"2023","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.015_bib25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/ene.14096","article-title":"Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study","volume":"27","author":"Adrichem","year":"2020","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2025.05.015_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2025.05.015_bib27","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1007\/s10072-024-07640-3","article-title":"Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): a comprehensive systematic review of clinical studies and meta-analysis","volume":"45","author":"Ramzi","year":"2024","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.015_bib28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/jns.12573","article-title":"Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial","volume":"28","author":"Bril","year":"2023","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"10.1016\/j.ncl.2025.05.015_bib29","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2025.05.015_bib30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2025.05.015_bib31","article-title":"Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment","author":"Levine","year":"2024","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.ncl.2025.05.015_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial","volume":"9","author":"van Schaik","year":"2010","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2025.05.015_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.015_bib34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archneur.62.2.249","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone","volume":"62","author":"Lopate","year":"2005","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2025.05.015_bib35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N Engl J Med"},{"issue":"Pt 4","key":"10.1016\/j.ncl.2025.05.015_bib36","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ncl.2025.05.015_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","year":"2009","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2025.05.015_bib38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.015_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jns.12287","article-title":"Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases","volume":"23","author":"Roux","year":"2018","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1016\/j.ncl.2025.05.015_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.26804","article-title":"Rituximab in refractory chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Muley","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2025.05.015_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421999631","article-title":"Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study","volume":"14","author":"Motte","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1016\/j.ncl.2025.05.015_bib42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.nmd.2013.06.006","article-title":"196th ENMC international workshop: outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands","volume":"23","author":"Vanhoutte","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.ncl.2025.05.015_bib43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","article-title":"Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice","volume":"15","author":"Gorson","year":"2010","journal-title":"J Peripher Nerv Syst"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:19:42Z","timestamp":1761592782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0733861925000349"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.05.015","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Inflammatory Demyelinating Polyneuropathy and Variants","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}